Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05518578




Registration number
NCT05518578
Ethics application status
Date submitted
23/08/2022
Date registered
26/08/2022
Date last updated
20/03/2023

Titles & IDs
Public title
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
Scientific title
RENAISSANCE Study: A Phase 2, Multicenter, Open Label Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
Secondary ID [1] 0 0
817P202
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Neurological 0 0 0 0
Epilepsy
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SPN-817

Experimental: Open-Label Treatment - 0.25 mg to 4 mg SPN-817 taken orally twice daily


Treatment: Drugs: SPN-817
oral capsule
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Effects of SPN-817 on safety and tolerability
Timepoint [1] 0 0
72 weeks
Secondary outcome [1] 0 0
Effect of SPN-817 on the motor seizure frequency
Timepoint [1] 0 0
72 weeks
Secondary outcome [2] 0 0
Effect of SPN-817 on the motor seizure frequency treatment response rate
Timepoint [2] 0 0
20 weeks
Secondary outcome [3] 0 0
Effect of SPN-817 on seizure-free rate
Timepoint [3] 0 0
20 weeks
Secondary outcome [4] 0 0
Effect of SPN-817 on time to event analysis
Timepoint [4] 0 0
64 weeks
Secondary outcome [5] 0 0
Effect of SPN-817 on incidence of motor seizure-free days.
Timepoint [5] 0 0
72 weeks
Secondary outcome [6] 0 0
Effect of SPN-817 on the Clinical Global Impression - Improvement (CGI-I) scale
Timepoint [6] 0 0
72 weeks
Secondary outcome [7] 0 0
Effect of SPN-817 on the Clinical Global Impression - Severity (CGI-S) scale
Timepoint [7] 0 0
72 weeks
Secondary outcome [8] 0 0
Effect of SPN-817 on the Quality of Life in Epilepsy (QOLIE-31-P; v2.0) questionnaire
Timepoint [8] 0 0
72 weeks
Secondary outcome [9] 0 0
Effect of SPN-817 on the Seizure Related Disability Assessment Scale (SERDAS) scale
Timepoint [9] 0 0
72 weeks

Eligibility
Key inclusion criteria
1. A diagnosis of treatment resistant epilepsy as adjudicated by the Epilepsy Study
Consortium.

2. Is male or female, aged 18 to = 70 years at screening.

3. Is able to read, understand, and sign the Informed Consent Form (ICF). If the
participant is unable to sign informed consent, a Legally Authorized Representative
(LAR) will complete the ICF.

4. Ability to keep accurate seizure diaries (with the aid of a caregiver as needed).

5. Weight within the normal or overweight ranges according to accepted values of the Body
Mass Index Chart (18.0 to 35 kg/m2).

6. Is able to swallow capsules whole without crushing, chewing, or cutting.

7. Is willing to adhere to all study procedures and able to attend study visits within
the specified time windows.

8. Failure of at least 2 tolerated, appropriately chosen and adequately dosed ASM drug
schedules to achieve sustained seizure freedom.

9. Taking at least 1 ASM at Screening and Baseline.

10. At least 4 seizures accepted by the Epilepsy Study Consortium for the secondary
outcome (adjudicated as "probable seizures" that are countable) during the 42-day
baseline seizure diary period, and no more than a 21-day period that was seizure-free.

11. A clinical diagnosis of Focal Cortical Dysplasia (FCD) Type I or Type II
(approximately n=10) confirmed by:

1. Likely FCD supported by neuroimaging that has been performed in the last 5 years,
or

2. History of surgical resection of the cortical dysplasia that is
histopathologically confirmed in patients who continue to have uncontrolled
seizures without a compelling alternate explanation for ongoing seizures.

Note: The Epilepsy Study Consortium will review to confirm FCD/probable FCD diagnosis.

12. Be in good general health in the judgment of the PI based upon medical history,
physical examination, standard 12-lead ECG, and clinical laboratory evaluations
obtained during the Screening Period

13. Be able to comply with all study-specified procedures.

14. Non-pregnant females of childbearing potential (FOCP) who are either sexually inactive
(abstinent) or, if sexually active with a male partner who is biologically capable of
having children, must agree to use one of the following acceptable birth control
methods beginning 30 days prior to the first dose of SPN-817, throughout the study,
and for 30 days following the last dose:

1. Simultaneous use of male condom and intra-uterine contraceptive device (IUD)
placed at least 4 weeks prior to first SPN-817 administration

2. Surgically sterile male partner

3. Simultaneous use of male condom and diaphragm with spermicide

4. Established hormonal contraceptive

Females are considered not to be of childbearing potential if they are either
post-menopausal (amenorrhea for at least 2 years and serum follicle stimulating
hormone [FSH] level of >40 IU/L) or permanently sterilized (e.g., bilateral tubal
ligation, hysterectomy, bilateral oophorectomy) for 6 months minimum.

15. Males must:

1. Use 2 methods of contraception in combination if his female partner is of
childbearing potential; this combination of contraceptive methods must be used
from the Screening Visit to = 1 month after the last dose of SPN-817, or

2. Have been surgically sterilized prior to the Screening Visit.

3. Refrain from donating any sperm until completion of the EOS Visit.

16. Patients who were previously enrolled in the BNI-02-1b FIAS study and benefited from
the treatment, following the approval by both the PI and the sponsor to be enrolled in
this study.
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Has taken huperzine A within the past year, with the exception of patients who were
previously enrolled in the BNI-02-1b FIAS study, benefited from the treatment, and
approved by the PI and the sponsor to be enrolled in this study.

2. Is planning to become pregnant or impregnate spouse, not using an acceptable method of
birth control (defined as use of double-barrier birth control methods, use of oral
contraceptives, or surgical sterilization), pregnant, or nursing.

3. Patients with combined focal and generalized syndrome as evidenced by severe
developmental delay and multiple seizure types, confirmed by EEG (e.g., Lennox-Gastaut
syndrome). Patient should also be excluded in case of non-diagnostic information.

4. Has non-epileptic events that could be confused by the patient and/or study staff as
epileptic seizures.

5. Has only seizures that are difficult to count; for example, has seizures that are not
clinically observable.

6. Has a history of only seizure clusters, for example, seizure clusters defined as
multiple seizures with at least one seizure within 30 minutes of the previous seizure.

7. Has a history of status epilepticus in the 6 months prior to Screening.

8. Change in ASM regimen in the last 28 days prior to Screening. No changes in ASMs are
allowed throughout the study period.

9. Vagus nerve stimulation (VNS), deep brain stimulation (DBS), responsive
neurostimulator system (RNS), or other neurostimulation for epilepsy device implanted
or activated <1 year prior to Screening; stimulation parameters that have been stable
for <3 months; battery life of unit not anticipated to extend for duration of trial;
or epilepsy surgery <1 year prior to Screening.

10. Active suicidal plan/intent in the past 6 months, or a history of suicide attempt in
the last 2 years, or more than 1 lifetime suicide attempt. History of suicidal
ideation.

11. Any condition that may impact a patient's ability to follow study procedures or a
patient's safety, based on what is known about the pharmacology/toxicology profile of
the trial agent(s).

12. Has a pre-existing medical condition (including an existing progressive or
degenerative neurological disorder including brain tumor, active encephalitis, active
meningitis or abscess) or takes medications that, in the PI's opinion, could interfere
with the patient's suitability for participation in the study.

13. Has a history or evidence of current significant psychiatric disturbance (e.g.,
schizophrenia, schizoaffective, or bipolar disorder) that would preclude meaningful
participation in the study procedures.

14. A history in the past 2 years or evidence of current alcohol and/or substance use
disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders 5th
edition.

15. Has had any clinical laboratory abnormalities within the 2 months prior to screening
considered of clinical significance by the PI.

16. Is HIV/Hepatitis B/Hepatitis C positive or has a positive urine drug screen.

17. Tobacco use as indicated by >5 cigarettes per week or the equivalent, 30 days prior to
Day -1.

18. Is on concomitant therapy with non-ASMs that are cholinergic.

19. Is currently taking or within the 3 days prior to enrollment has taken
Epigallocatechin gallate (EGCG); or consumed foods or drinks containing EGCG,
including green, white, or oolong teas and certain black teas, or food containing >100
grams of carob powder. EGCG cannot be consumed throughout the study.

20. Has participated in any clinical investigational drug or device study within 4 weeks
prior to study entry or within 5 half-lives of the clinical investigational drug,
whichever is longer.

21. Clinically significant cardiologic abnormalities at Screening. One repeat assessment
is allowed per investigator discretion.

1. Abnormal ECG that is, in the investigator's opinion, clinically significant
including heart rate (HR) <50 bpm (average of 3 recordings)

2. PR interval > 220 ms

3. QRS interval = 120 ms

4. QTcF (QT corrected for heart rate using Fridericia's method) interval > 450 ms
for males and interval > 475 ms for females

5. Second or third-degree atrioventricular block

6. Any rhythm, other than sinus rhythm, that is interpreted by the investigator to
be clinically significant

22. Creatinine clearance < 90 mL/min, according to the Cockcroft-Gault equation at
Screening.

23. Clinically significant vital sign abnormalities (systolic blood pressure lower than 90
or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or HR less
than 50 or over 100 bpm) at Screening.

24. Patient has had greater than 2 allergic reactions to an ASM or one serious
hypersensitivity reaction to an ASM.

25. Patients who donated 50 to 499 mL of blood within 30 days or more than 499 mL within
56 days prior to Day 1 dosing or have hemoglobin <128 g/L (males) or <115 g/L
(females) and hematocrit <0.37 L/L (males) or <0.32 L/L (females) at Screening.
Following screening and throughout the study, patient should not donate blood.

26. Any reason which, in the opinion of the PI, would prevent the patient from
participating in the study

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/02/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2025
Actual
Sample size
Target
35
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Supernus Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jonathan Rubin, MD, MBA
Address 0 0
Supernus Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Neeti Mehta, PhD
Address 0 0
Country 0 0
Phone 0 0
240-403-5838
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/ct2/show/NCT05518578